PCSK9 and Hypercholesterolemia: One LNP utilizing GalNAc is inclisiran, a PCSK9 siRNA GalNAc-LNP that has demonstrated lasting reductions in LDL cholesterol for up to 6 months and is currently approved for use in patients with hypercholesterolaemia.123